The role of alprazolam for the treatment of panic disorder in Australia

@article{Moylan2012TheRO,
  title={The role of alprazolam for the treatment of panic disorder in Australia},
  author={S. Moylan and F. Giorlando and T. Nordfj{\ae}rn and M. Berk},
  journal={Australian \& New Zealand Journal of Psychiatry},
  year={2012},
  volume={46},
  pages={212 - 224}
}
Objective: To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature. Methods: Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles. Clinical practice guidelines from the American Psychiatric Association, National Institute of Clinical Excellence, Royal… Expand
Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis.
TLDR
This study indicates that for those who respond to an initial 8-week treatment, continuing BZDs is equivalent to antidepressants in efficacy and safety, however, the limited number of studies warranted further investigations of the long-term effectiveness and safety of BzDs. Expand
Reconsidering benzodiazepines in the treatment of panic disorder
  • V. Starcevic
  • Medicine
  • The Australian and New Zealand journal of psychiatry
  • 2012
TLDR
The role of alprazolam in the treatment of panic disorder (PD) in Australia and conclusion that it “merits renewed consideration” is examined and Moylan et al. (2012) call for further scrutiny of the underlying issues. Expand
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology.
TLDR
The oppositional neuropharmacological interactions between chronic benzodiazepine use and antidepressant mechanism of action, which could result in reduced antidepressant efficacy and function in depression are discussed. Expand
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011
TLDR
There was a 58.2% increase in the dispensing of psychotropic drugs in Australia from 2000 to 2011, driven by major increases in antidepressants, atypical antipsychotics and ADHD medications. Expand
The Prevalence of Alprazolam Uses in Geriatric Patients at Dr. Mohammad Hoesin Hospital Palembang
TLDR
The aim of this study was to determine the prevalence of the use of alprazolam and the indication of usage was atheroscerotic heart disease, diarrhoea and gastroenteritis of presumed infectious origin, unspecified gastritis, and thyrotoxic heart disease. Expand
Alprazolam and wider benzodiazepine misuse in Australia – sources of supply and evidence of harms
TLDR
The submission cited two references to substantiate their counterclaim, but neither of these was relevant to the issue at hand and the empirical basis of the submission was flawed. Expand
Alprazolam Dependence – The Sting in the Tail: A Case Report
TLDR
A 38-year old female seen in the emergency department after ingesting a total of 99 alprazolam tablets amounting to approximately 50 mg of alpazolam over the previous two days has a strong family history of both suicide and bipolar I disorder. Expand
Benzodiazepine prescribing: a qualitative cross-national comparative pilot between Australia and South Africa.
[Extract] Benzodiazepines have anxiolytic, sedative, hypnotic and muscle relaxant effects and are used to treat anxiety, panic and sleep disorders. They may result in an altered mental state,Expand
Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling.
TLDR
Alprazolam rescheduling appears to have been effective in reducing alpazolam use in this high-risk population of clients in OST, without substitution with other drugs, in the short term. Expand
Psychotropic Medicine Utilization in Older People in New Zealand from 2005 to 2013
TLDR
There was a marked increase in utilization of recently funded antidepressants and atypical antipsychotics, and there was a move towards utilization of selective serotonin reuptake inhibitors in New Zealand. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 131 REFERENCES
Discontinuation of Alprazolam after successful treatment of panic disorder: a naturalistic follow-up study
Low rates of benzodiazepine discontinuation have been seen in long- term outcome studies of alprazolam-treated panic disorder. Discontinuation studies reveal high rates of relapse when alprazolam isExpand
Discontinuation reactions to alprazolam in panic disorder.
TLDR
This paper discusses data from three discontinuation studies with alprazolam, which revealed a marked exacerbation of symptoms during the end of the tapering period and the first week without medication, which was followed by improvement during the second post-taper week. Expand
The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder
TLDR
The available evidence fails to demonstrate alprazolam as superior to other benzodiazepines for the treatment of panic disorder, and statistical heterogeneity on prespecified outcomes was not eliminated by stratification on baseline anxiety level. Expand
The development of clonazepam as a psychotropic: the massachusetts general hospital experience.
TLDR
In response to the apparent problematic pharmacokinetics of alprazolam, members of the MGH psychiatry department pursued investigation that ultimately established the antipanic efficacy of clonazepam as well as examined its effectiveness in the treatment of other disorders, such as bipolar disorder and social phobia. Expand
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
TLDR
An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine. Expand
A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.
TLDR
Alprazolam demonstrates efficacy for the treatment of anxiety disorders, panic disorder, and depression in the large majority of studies; for these illnesses, it appeared equal in efficacy to the active agents with which it was compared. Expand
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
TLDR
The different time courses of therapeutic action of imipramine and alprazolam indicate that these drugs ameliorate panic anxiety via different mechanisms, and support the hypotheses that drugs that are efficacious in the treatment of panic disorders act by altering noradrenergic function and that drugs with primary actions on serotonin function are likely to be less effective treatments. Expand
Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder.
TLDR
The data suggest that most patients maintain benefit with long-term pharmacotherapy but that residual symptomatology may require more intensive or additional treatment strategies, and underscore the potential importance of comorbid affective and anxiety disorders as well as phobic patterns in determining long- term response to treatment. Expand
The role of lamotrigine in the management of bipolar disorder
TLDR
It would seem prudent to await greater evidence of efficacy before designating lamotrigine as first-line treatment for other bipolar indications, as the strongest evidence for its efficacy lies in the prevention of bipolar depression. Expand
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
TLDR
Evidence that the serotonergic system plays a significant role in the anti-panic properties of these two SSRIs is supported, and paroxetine and citalopram show similar anti- panic properties and a good tolerability profile. Expand
...
1
2
3
4
5
...